Analysis of the structure of mycolic acids of Mycobacterium simiae reveals a particular composition of alpha-mycolates in strain 'habana' TMC 5135, considered as immunogenic in tuberculosis and leprosy.
Structural analysis of mycolic acids from Mycobacterium simiae (including some 'habana' strains) was carried out using (1)H-NMR and MS. Results indicated that this species presents a general pattern of alpha-, alpha'- and keto-mycolates. alpha-Mycolates were composed of a complex mixture of 82 to 89 carbon atoms (C82-C89), with the predominant molecular species containing two di-substituted cyclopropane rings. Among keto-mycolates (C84-C89), those containing one trans di-substituted cyclopropane ring were the most abundant. The alpha'-mycolates were monounsaturated (C64, C66). According to MS and (1)H-NMR data, the strains studied differed in fine structural details of alpha-mycolates and keto-mycolates. Notably, strain 'habana' TMC 5135 (belonging to the 'habana' group, and considered as highly immunogenic in tuberculosis and leprosy) presented a particular composition of alpha-mycolates, with a major component (C87) containing one cis plus one trans di-substituted cyclopropane ring, unlike the type strain of M. simiae and other strains of the 'habana' group (IPK-220 and IPK-337R), in which the major component (C84) contained two cis di-substituted cyclopropane rings. In spite of this finding, the 'habana' strains were closely related to each other and mainly differed from the type strain of M. simiae in some details of the fine structure of keto-mycolates. The present work indicated that within an identical general pattern of mycolic acids, there is a complex composition in M. simiae and structural variation among different strains, as reported for pathogenic species of the genus. Noteworthy was the particular composition of alpha-mycolates in strain 'habana' TMC 5135.
Laboratorio Nacional de Referencia e Investigaciones en Tuberculosis y Micobacterias, Centro Colaborador OPS/OMS, Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba.
Lilian
L
Mederos
Laboratorio Nacional de Referencia e Investigaciones en Tuberculosis y Micobacterias, Centro Colaborador OPS/OMS, Instituto de Medicina Tropical Pedro Kourí (IPK), La Habana, Cuba.
José A
JA
Valdivia
Departamento de Genética y Microbiología, Facultad de Medicina y Odontología, Universidad de Murcia, Spain.
Pedro L
PL
Valero-Guillén
D000818:Animals; D001428:Bacterial Vaccines / Q000276:immunology; D006801:Humans; D007918:Leprosy / Q000276:immunology / Q000517:prevention & control; D009682:Magnetic Resonance Spectroscopy; D013058:Mass Spectrometry; D009171:Mycolic Acids / Q000737:chemistry* / Q000276:immunology*; D009170:Nontuberculous Mycobacteria / Q000378:metabolism*; D013045:Species Specificity; D032581:Tuberculosis Vaccines / Q000276:immunology
D001428:Bacterial Vaccines; D009171:Mycolic Acids; D032581:Tuberculosis Vaccines